189 related articles for article (PubMed ID: 26453693)
1. Defining a New Prognostic Index for Stage I Nonseminomatous Germ Cell Tumors Using CXCL12 Expression and Proportion of Embryonal Carcinoma.
Gilbert DC; Al-Saadi R; Thway K; Chandler I; Berney D; Gabe R; Stenning SP; Sweet J; Huddart R; Shipley JM
Clin Cancer Res; 2016 Mar; 22(5):1265-73. PubMed ID: 26453693
[TBL] [Abstract][Full Text] [Related]
2. Prediction of relapse in stage I testicular germ cell tumor patients on surveillance: investigation of biomarkers.
Lobo J; Gillis AJM; van den Berg A; Looijenga LHJ
BMC Cancer; 2020 Aug; 20(1):728. PubMed ID: 32758242
[TBL] [Abstract][Full Text] [Related]
3. Outcomes of surveillance protocol of clinical stage I nonseminomatous germ cell tumors-is shift to risk adapted policy justified?
Divrik RT; Akdoğan B; Ozen H; Zorlu F
J Urol; 2006 Oct; 176(4 Pt 1):1424-29; discussion 1429-30. PubMed ID: 16952649
[TBL] [Abstract][Full Text] [Related]
4. Outcome of patients with stage II and III nonseminomatous germ cell tumors: results of a single center.
Ataergin S; Ozet A; Arpaci F; Kilic S; Beyzadeoglu M; Komurcu S
Indian J Cancer; 2007; 44(1):6-11. PubMed ID: 17401218
[TBL] [Abstract][Full Text] [Related]
5. Comparative Effectiveness of Risk-adapted Surveillance vs Retroperitoneal Lymph Node Dissection in Clinical Stage I Nonseminomatous Germ Cell Testicular Cancer: A Retrospective Follow-up Study of 81 Patients.
Fan G; Zhang L; Yi L; Jiang ZQ; Ke Y; Wang XS; Xiong YY; Han WQ; Zhou X; Liu C; Yu X
Asian Pac J Cancer Prev; 2015; 16(8):3267-72. PubMed ID: 25921130
[TBL] [Abstract][Full Text] [Related]
6. Epidermal growth factor receptor and epididymis invasion as prognostic biomarkers in clinical stage I testicular germ cell tumours.
Sanmamed MF; Esteban E; Uriol E; Zarate R; Capelan M; Muriel C; Crespo G; Berros JP; Pardo-Coto P; Perez Q; Alvarez-Fernández C; Jiménez Fonseca P; Luque M; Astudillo A
J Transl Med; 2017 Mar; 15(1):62. PubMed ID: 28320414
[TBL] [Abstract][Full Text] [Related]
7. CXCL12 expression is an adverse predictor for disease recurrence in patients with metastatic non-seminomatous testicular germ cell tumors.
Fankhauser CD; Roth L; Grossmann NC; Kranzbühler B; Eberli D; Sulser T; Moch H; Bode PK; Beyer J; Hermanns T
BMC Cancer; 2019 Aug; 19(1):802. PubMed ID: 31412792
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical expression of P53 tumor suppressor gene protein in adult germ cell testis tumors: clinical correlation in stage I disease.
Lewis DJ; Sesterhenn IA; McCarthy WF; Moul JW
J Urol; 1994 Aug; 152(2 Pt 1):418-23. PubMed ID: 8015085
[TBL] [Abstract][Full Text] [Related]
9. Outcomes of surveillance versus adjuvant chemotherapy for patients with stage IA and IB nonseminomatous testicular germ cell tumors.
Gumus M; Bilici A; Odabas H; Ustaalioglu BBO; Kandemir N; Demirci U; Cihan S; Bayoglu IV; Ozturk T; Turkmen E; Urakci Z; Seker MM; Gunaydin Y; Selcukbiricik F; Turan N; Sevinc A
World J Urol; 2017 Jul; 35(7):1103-1110. PubMed ID: 27812752
[TBL] [Abstract][Full Text] [Related]
10. Flow cytometric and quantitative histological parameters to predict occult disease in clinical stage I nonseminomatous testicular germ cell tumors.
Moul JW; Foley JP; Hitchcock CL; McCarthy WF; Sesterhenn IA; Becker RL; Griffin JL
J Urol; 1993 Sep; 150(3):879-83. PubMed ID: 8393944
[TBL] [Abstract][Full Text] [Related]
11. Risk stratification of pubertal children and postpubertal adolescents with clinical stage I testicular nonseminomatous germ cell tumors.
Cost NG; Lubahn JD; Adibi M; Romman A; Wickiser JE; Raj GV; Sagalowsky AI; Margulis V
J Urol; 2014 May; 191(5 Suppl):1485-90. PubMed ID: 24679874
[TBL] [Abstract][Full Text] [Related]
12. Proliferating cell nuclear antigen expression to predict occult disease in clinical stage I nonseminomatous testicular germ cell tumors.
Fernandez EB; Sesterhenn IA; McCarthy WF; Mostofi FK; Moul JW
J Urol; 1994 Oct; 152(4):1133-8. PubMed ID: 7915335
[TBL] [Abstract][Full Text] [Related]
13. Prognostic risk factors that identify patients with clinical stage I nonseminomatous germ cell tumors at low risk and high risk for metastasis.
Heidenreich A; Sesterhenn IA; Mostofi FK; Moul JW
Cancer; 1998 Sep; 83(5):1002-11. PubMed ID: 9731905
[TBL] [Abstract][Full Text] [Related]
14. Interobserver Agreement in Vascular Invasion Scoring and the Added Value of Immunohistochemistry for Vascular Markers to Predict Disease Relapse in Stage I Testicular Nonseminomas.
Lobo J; Stoop H; Gillis AJM; Looijenga LHJ; Oosterhuis W
Am J Surg Pathol; 2019 Dec; 43(12):1711-1719. PubMed ID: 31490238
[TBL] [Abstract][Full Text] [Related]
15. Risk-adapted treatment choice in stage I nonseminomatous testicular germ cell cancer by regarding vascular invasion in the primary tumor: a prospective trial.
Pont J; Höltl W; Kosak D; Machacek E; Kienzer H; Julcher H; Honetz N
J Clin Oncol; 1990 Jan; 8(1):16-20. PubMed ID: 1688613
[TBL] [Abstract][Full Text] [Related]
16. Clinical and biological significance of CXCL12 and CXCR4 expression in adult testes and germ cell tumours of adults and adolescents.
Gilbert DC; Chandler I; McIntyre A; Goddard NC; Gabe R; Huddart RA; Shipley J
J Pathol; 2009 Jan; 217(1):94-102. PubMed ID: 18839394
[TBL] [Abstract][Full Text] [Related]
17. alpha-Catenin expression pattern and DNA image-analysis cytometry have no additional value over primary histology in clinical stage I nonseminomatous testicular cancer.
Spermon JR; De Wilde PC; Hanselaar AG; Schaafsma HE; Ruijter TE; Witjes JA; Van Moorselaar RJ
BJU Int; 2002 Feb; 89(3):278-84. PubMed ID: 11856111
[TBL] [Abstract][Full Text] [Related]
18. A refined risk stratification scheme for clinical stage 1 NSGCT based on evaluation of both embryonal predominance and lymphovascular invasion.
Lago-Hernandez CA; Feldman H; O'Donnell E; Mahal BA; Perez V; Howard S; Rosenthal M; Cheng SC; Nguyen PL; Beard C; D'Amico AV; Sweeney CJ
Ann Oncol; 2015 Jul; 26(7):1396-401. PubMed ID: 25888612
[TBL] [Abstract][Full Text] [Related]
19. Lymphovascular invasion and presence of embryonal carcinoma as risk factors for occult metastatic disease in clinical stage I nonseminomatous germ cell tumour: a systematic review and meta-analysis.
Blok JM; Pluim I; Daugaard G; Wagner T; Jóźwiak K; Wilthagen EA; Looijenga LHJ; Meijer RP; Bosch JLHR; Horenblas S
BJU Int; 2020 Mar; 125(3):355-368. PubMed ID: 31797520
[TBL] [Abstract][Full Text] [Related]
20. [Histopathologic and biological prognostic factors of clinical stage I non-seminomatous germ cell tumors. Implications for risk-adjusted therapy].
Heidenreich A; Sesterhenn IA; Mostofi FK; Moul JW; Engelmann UH
Urologe A; 1999 Mar; 38(2):168-78. PubMed ID: 10231939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
